Requires robust thermal management and higher-quality cells
At the end of 2023, the journal Science named the GLP-1 class of drugs the top 10 scientific breakthroughs of the year (Science's 2023 Breakthrough of the Year), while Nature named GLP-1 research pioneer Svetlana Mojsov as one of the top 10 people of the year of the year
The implications extend beyond individual peptide candidates
Novo Nordisks Catalent acquisition highlights the value of owning fill-finish capacity: the three Catalent sites specialize in sterilization and fill/finish of injectables ( [10] )
Common problems include inconsistent dosing, label discrepancies, and endotoxin contaminants like lipopolysaccharides, which can provoke systemic inflammation
*AEMS is intended to help identify safety concerns related to marketed products, but it does not prove any product or drug is linked or caused a particular side effect or injury